Prevalidation of Salivary Biomarkers for Oral Cancer Detection
Penn collection
Degree type
Discipline
Subject
Aged
Carcinoma
Squamous Cell
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Feasibility Studies
Female
Follow-Up Studies
Genotype
Humans
Interleukin-8
Los Angeles
Male
Middle Aged
Mouth Neoplasms
Neoplasm Proteins
Prognosis
Real-Time Polymerase Chain Reaction
Retrospective Studies
RNA
Messenger
Saliva
Tumor Markers
Biological EMTREE drug terms: interleukin 8
messenger RNA
tumor marker EMTREE medical terms: adult
article
cancer diagnosis
case control study
cohort analysis
controlled study
female
human
human cell
human tissue
major clinical study
male
mouth cancer
national health organization
priority journal
protein expression
receiver operating characteristic
saliva analysis
salivary gland
sensitivity and specificity
squamous cell carcinoma
subcutaneous fat
Dentistry
Oral and Maxillofacial Surgery
Oral Biology and Oral Pathology
Periodontics and Periodontology
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Contributor
Abstract
Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Results: Expression of all sevenmRNAand three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. ©2012 AACR.